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xerostomia were 13% and 17%, respectively. Tumor stage, unilateral 
neck irradiation, and tumor subsite (p<0.001) correlated with late 
toxicity. For the whole group, clinically relevant deterioration was 
seen on the QLQ-H&N35 dry mouth scale (-21, compared to baseline), 
while the scores on the QLQ-H&N35 swallowing were returned to 
baseline level. Unilateral neck irradiation was the most significant 
predictor for better scores on the QLQ-H&N35 dry mouth scale.  
Conclusions: Excellent outcomes were achieved in patients treated 
with 46 Gy of IMRT followed by a stereotactic body radiotherapy boost 
by means of the Cyberknife. No single failure was reported in patients 
with low tumor stage and HPV-related disease. This highly-conformal 
boost technique significantly reduced toxicity and improved QoL-
scores without jeopardizing outcomes. However, patient-reported 
xerostomia remains a major problem. Because unilateral neck 
irradiation was the most significant predictor for better scores on 
QLQ-H&N35 dry mouth scale, expanding the indications for this 
treatment approach needs to be thoroughly investigated in 
prospective trials. Given the increasing incidence of HPV-related OPC 
in the last decades especially among young patients, further reduction 
of the incidence of these troublesome complications is, therefore, 
mandatory.  
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Purpose/Objective: In radiation oncology 18F-FDG PET imaging has 
increasingly been investigated for prediction and monitoring of 
treatment response. The integrated SUV (iSUV) has been reported to 
be associated with treatment outcome in HNSCC. We investigated the 
predictive power of iSUV and its comparison with commonly used 18F-
FDG PET derived metrics (i. e. SUVmax, SUVmean), tumor volume and the 
TNM staging system in squamous cell carcinomas of the head and 
neck.  
Materials and Methods: Eightyone (cT1 – cT4) HNSCC patients treated 
with radiotherapy or chemo-radiation were included retrospectively. 
39 patients had a tumor of the larynx and 41 patients had an 
oropharynx tumor. All patients underwent an 18F-FDG-PET-CT scan for 
radiation treatment planning and the primary tumor was delineated 
by an experienced radiation oncologist on the fused images PET and 
CT images (Figure 1a). Basic SUV uptake metrics were extracted from 
the primary GTV, including SUVmax, SUVmean, and iSUV defined as the 
product of tumor volume and SUVmean. The non-parametric Mann-
Whitney U test and the log rank test were used to determine 
statistical significant differences on overall survival groups. For TNM 
the Chi-square test was used. Univariate Cox proportional-hazards 
models were used compared the risk of death among patients. A 5-
fold cross validated c-index was determined to evaluate the model’s 
performance. 
Results: The median survival time was 37 months (95% CI, 33-41 
months) and the median follow up was 30 months (range: 0.7-41), 
with an event rate of 28 %. iSUV was significantly associated with 
overall survival (p = 0.001) and showed a 5-fold cross validation c-
index of 0.78. The comparison with TNM and other evaluated 
parameters is summarized in Table 1. For comparison, Kaplan Meier 
curves are shown in Figure 1b.  
 
Table 1. Univariate association with overall survival 
 iSUV SUVmax SUVmean Tumor 
volume 
TNM 
Non-parametric test 
(p-value) 
0.001 0.011 0.080 0.000 0.135 
Log Rank test (p-
value) 
0.010 0.117 0.302 0.009 0.139 
C-index 0.78 0.70 0.62 0.77 0.68 
 
Conclusions: In line with previous findings, the integrated SUV is an 
important predictor of overall survival in HNSCC. The TNM staging 
system showed a limited value as prognostic factor. iSUV had a better 
prognostic performance than the most commonly used 18F-FDG-PET-CT 
derived metrics, however it was not a better predictor than tumor 
volume. Analysis of an extended cohort and a tumor anatomical sub-
location analysis will follow.  
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Purpose/Objective: Randomized controlled trials are the cornerstone 
of evidence-based medicine. Therefore, quality assurance (QA) of 
these trials is of vital importance. QA has various aspects, such as 
monitoring, image QA and treatment planning QA. We describe the 
latter aspect for a randomized international multicenter phase II trial 
for head and neck cancer: 'Adaptive and innovative Radiation 
Treatment FOR improving Cancer treatment outcomE (ARTFORCE)' 
(registered with ClinicalTrials.gov number NCT01504815).  
In ARTFORCE patients are randomized between chemoradiotherapy 
with concurrent cisplatin or Cetuximab and between standard 
radiotherapy (RT) and redistributed adaptive RT with a maximum dose 
up to 84Gy, resulting in four treatment arms (Figure 1). Because the 
planning of redistributed RT dose requires a novel approach, we will 
discuss its QA. 
 Materials and Methods: First, consensus was reached by the 
participating centers on delineation and treatment planning 
guidelines. A contouring atlas was made and dose objectives and 
constraints were set, which were subsequently used in the dummy 
run. For the dummy run, an anonymized CT scan and delineations 
were provided to all participating centers for treatment planning of 
